Form 4: Linda Maxwell Reports Acquisition of United Therapeutics Corp Stock Options
SEC Filing
Director Linda Maxwell reports the acquisition of 2,890 stock options in United Therapeutics Corp.
Summary
- Linda Maxwell, a director of United Therapeutics Corp, filed a Form 4 on July 26, 2024.
- The form reports the acquisition of 2,890 stock options on July 25, 2024, at a price of $0.
- These options are part of an annual non-employee director award and vest on the one-year anniversary of the grant date, July 25, 2025, and expire on July 25, 2034.
- Following the transaction, Maxwell directly owns 2,890 derivative securities.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it is a standard disclosure of stock option grants to a director.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.
Stakeholder Impact
- The transaction has a minimal direct impact on stakeholders, as it is a standard stock option grant.
Key Dates
| Date | Description |
|---|---|
| 07/25/2024 | Transaction date: Acquisition of stock options. |
| 07/25/2025 | Vesting date of the stock options. |
| 07/25/2034 | Expiration date of the stock options. |
| 07/26/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.